Tesamorelin

Tesamorelin is a synthetic GHRH analog studied in relation to endogenous growth hormone signaling, IGF-1 activity, and visceral adipose tissue regulation. Published clinical research has focused primarily on HIV-associated lipodystrophy, where tesamorelin has been investigated for reducing excess abdominal visceral fat while acting through the growth hormone axis.

What Tesamorelin has been studied for

• GH / IGF-1 axis signaling
• visceral adipose tissue reduction
• body-composition changes in HIV-associated lipodystrophy
• metabolic-marker research related to visceral fat

Relevant study
“Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation.” That trial reported about an 18% reduction in visceral fat and improvement in body-image distress in HIV-infected patients with central fat accumulation.